These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 38397999)

  • 21. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
    Medina-Julio D; Ramírez-Mejía MM; Cordova-Gallardo J; Peniche-Luna E; Cantú-Brito C; Mendez-Sanchez N
    Med Sci Monit; 2024 Jan; 30():e943417. PubMed ID: 38282346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa.
    Younossi ZM; Golabi P; Paik J; Owrangi S; Yilmaz Y; El-Kassas M; Alswat K; Alqahtani SA
    Liver Int; 2024 Apr; 44(4):1061-1070. PubMed ID: 38305642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Global Epidemic of Metabolic Fatty Liver Disease.
    Lee ECZ; Anand VV; Razavi AC; Alebna PL; Muthiah MD; Siddiqui MS; Chew NWS; Mehta A
    Curr Cardiol Rep; 2024 Apr; 26(4):199-210. PubMed ID: 38376745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome.
    Xu Q; Zhang J; Lu Y; Wu L
    iScience; 2024 Feb; 27(2):108783. PubMed ID: 38292434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Sawada K; Chung H; Softic S; Moreno-Fernandez ME; Divanovic S
    Cell Metab; 2023 Nov; 35(11):1852-1871. PubMed ID: 37939656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit.
    Roy S; Saha P; Bose D; Trivedi A; More M; Xiao S; Diehl AM; Chatterjee S
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
    Henin G; Loumaye A; Leclercq IA; Lanthier N
    JHEP Rep; 2024 Feb; 6(2):100963. PubMed ID: 38322420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Ramanathan R; Patwa SA; Ali AH; Ibdah JA
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
    Johanns M; Haas JT; Raverdy V; Vandel J; Chevalier-Dubois J; Guille L; Derudas B; Legendre B; Caiazzo R; Verkindt H; Gnemmi V; Leteurtre E; Derhourhi M; Bonnefond A; Froguel P; Eeckhoute J; Lassailly G; Mathurin P; Pattou F; Staels B; Lefebvre P
    JHEP Rep; 2024 Jan; 6(1):100948. PubMed ID: 38125300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic.
    Rao G; Peng X; Li X; An K; He H; Fu X; Li S; An Z
    Front Med (Lausanne); 2023; 10():1294267. PubMed ID: 38089874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.